Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Anticancer Res. 2013 Oct;33(10):4203–4212.

Figure 2.

Figure 2

Tumor tissue sections, immunohistochemically stained for TCII (TCN2 antibody, 10× objective), TCII-R (CD320 antibody, 10× objective) and Ki-67 (MIB-1 antibody, 40× objective), are shown from left to right for each xenograft tissue sample: (1) breast carcinoma MCF7/S; (2) Breast carcinoma MDA-MB-231; (3) breast carcinoma ZR-75-1; (4) cervical carcinoma C-33A; (5) cervical carcinoma Ca Ski; (6) cervical carcinoma HeLa; (7) colonic carcinoma HCT-116; (8) colonic adenocarcinoma HT-29; (19) epidermoid carcinoma A431NS; (10) Ewing’s sarcoma CHP-100; (11) glioblastoma multiforme SF-767; (12) leukemia MDS/SP1; (13) B-cell lymphoma Granta-4; (14) Burkitt’s lymphoma Ramos; (15) Burkitt’s lymphoma Raji; (16) melanoma A375; (17) non-small cell lung cancer (NSCLC) adenocarcinoma H1975; (18) NSCLC carcinoma MV-522; (19) NSCLC carcinoma NCI: H460; (20) ovarian carcinoma 2780AD; (21) ovarian carcinoma NIH-OVCAR-3; (22) pancreatic adenocarcinoma AsPC-1; (23) pancreatic adenocarcinoma BxPC-3; (24) pancreatic adenocarcinoma CAPAN-2; (25) pancreatic adenocarcinoma CFPAC-1; (26) pancreatic adenocarcinoma HPAF-II; (27) pancreatic adenocarcinoma MIA PaCa-2; (28) pancreatic carcinoma Panc-1; (29) pancreatic carcinoma SU.86.86; (30) prostatic carcinoma DU-145; (31) prostatic adenocarcinoma PC-3; (32) renal adenocarcinoma ACHN; (33) renal carcinoma Caki; and (34) uterine epithelial carcinoma RL 95-2.